Viking Therapeutics Inc (NASDAQ:VKTX) – Research analysts at Zacks Investment Research boosted their FY2016 earnings per share (EPS) estimates for shares of Viking Therapeutics in a research note issued to investors on Tuesday. Zacks Investment Research analyst D. Bautz now expects that the brokerage will post earnings of ($0.97) per share for the year, up from their prior forecast of ($1.06).

Several other research firms have also weighed in on VKTX. HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of Viking Therapeutics in a report on Sunday, September 18th. Maxim Group set a $5.00 target price on Viking Therapeutics and gave the stock a “buy” rating in a report on Thursday, August 11th. Finally, Laidlaw reduced their target price on Viking Therapeutics from $20.00 to $10.00 and set a “buy” rating for the company in a report on Thursday, August 11th.

Earnings History and Estimates for Viking Therapeutics (NASDAQ:VKTX)

Shares of Viking Therapeutics (NASDAQ:VKTX) opened at 1.15 on Friday. The firm has a 50-day moving average price of $1.15 and a 200-day moving average price of $1.26. The company’s market capitalization is $22.17 million. Viking Therapeutics has a 1-year low of $0.94 and a 1-year high of $5.17.

Viking Therapeutics (NASDAQ:VKTX) last posted its earnings results on Thursday, November 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.01.

An institutional investor recently raised its position in Viking Therapeutics stock. Sio Capital Management LLC raised its position in Viking Therapeutics Inc (NASDAQ:VKTX) by 53.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 849,905 shares of the company’s stock after buying an additional 295,523 shares during the period. Viking Therapeutics comprises 0.8% of Sio Capital Management LLC’s holdings, making the stock its 24th largest position. Sio Capital Management LLC owned approximately 4.41% of Viking Therapeutics worth $1,191,000 as of its most recent SEC filing.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.

5 Day Chart for NASDAQ:VKTX

Receive News & Stock Ratings for Viking Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics Inc and related stocks with our FREE daily email newsletter.